Global Information
회사소개 | 문의 | 비교리스트

유기인산 및 카바메이트 중독 : 파이프라인 리뷰

Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 357980
페이지 정보 영문 38 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


유기인산 및 카바메이트 중독 : 파이프라인 리뷰 Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 38 Pages

유기인산 및 카바메이트는 일반적인 살충제이며, 콜린에스테라제 활성을 저해하고, 급성 무스카린 유사 작용(타액 분비, 유루, 배뇨, 설사, 구토, 기관지루, 기관지 경련, 서맥, 축동), 근연축, 근력 저하 등의 니코틴 유사 작용을 일으킵니다. 대부분의 환자에게는 서맥 작용이 나타나며, 중독이 심하면 저혈압증이 나타나는 경우도 있습니다. 중추신경계 독성이 일반적이며, 발작이나 흥분을 수반하기도 하고, 권태감에 빠지거나 혼수상태에 이르는 일도 자주 있습니다. 췌장염이 될 가능성도 있으며, 유기인산에스테르에 의해 심장블록이나 QT 간격 연장 등과 같은 부정맥이 발생하기도 합니다.

유기인산 및 카바메이트 중독(Organophosphate And Carbamate Poisoning) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

유기인산 및 카바메이트 중독 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

유기인산 및 카바메이트 중독 치료제 개발 참여 기업

  • Countervail Corporation
  • Hager Biosciences, LLC

약제 개요

유기인산 및 카바메이트 중독 : 개발이 중지된 제품

유기인산 및 카바메이트 중독 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.06.23

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Organophosphate and Carbamate Poisoning - Pipeline by AntoXa Corp, H1 2020
  • Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, H1 2020
  • Organophosphate and Carbamate Poisoning - Pipeline by PlantVax Inc, H1 2020
  • Organophosphate and Carbamate Poisoning - Dormant Projects, H1 2020
  • Organophosphate and Carbamate Poisoning - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides an overview of the Organophosphate and Carbamate Poisoning (Other Diseases) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Other Diseases).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Other Diseases) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Other Diseases)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Other Diseases).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Other Diseases) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Organophosphate and Carbamate Poisoning - Overview
    • Organophosphate and Carbamate Poisoning - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Organophosphate and Carbamate Poisoning - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
    • AntoXa Corp
    • Countervail Corp
    • PlantVax Inc
  • Organophosphate and Carbamate Poisoning - Drug Profiles
    • AM-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galantamine hydrobromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PlantVax-1502-HN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RS-194B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Organophosphate and Carbamate Poisoning - Dormant Projects
  • Organophosphate and Carbamate Poisoning - Discontinued Products
  • Organophosphate and Carbamate Poisoning - Product Development Milestones
    • Featured News & Press Releases
      • Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q